Evaluation of COVID-19 clinical features and outcomes in individuals with rheumatic disease
Öz
features and course of coronavirus disease 2019 (COVID-19) in individuals with rheumatic disease.
Materials and Methods: This retrospective study was carried out at the Erciyes University rheumatology outpatient clinic from July 1 to August 1, 2021. The demographic and clinical data and summarized COVID-19 history, clinical course of COVID-19, fatigue, and pain levels of patients with rheumatic disease were obtained from our institutional electronic registration database and patient files.
Results: Recruited participants were 106 individuals (83% female, %17 male) with rheumatic disease who had been confirmed by laboratory tests to have COVID-19 and recovered from the COVID-19 infection. Their mean age and body mass index (BMI) were 48.69±11.5 years and 29.89±6.76 kg/m2, respectively. Additionally, 21 (19.8%) had been hospitalized, and five (4.7%) had been admitted to the intensive care unit. The most common rheumatic diseases were axial spondyloarthritis (40; 37.7%) and rheumatoid arthritis (26 cases; 24.5%). Patients who received conventional synthetic disease-modifying drugs (csDMARDs) reportedly experienced more pain, fatigue, and headaches than those in the biologic agent and non-steroidal anti-inflammatory drug (NSAID) groups.
Conclusion: Our study results reveal similar symptoms and hospitalization rates among patients with rheumatic disease who recovered from COVID-19 and received either csDMARDs, biologic agents, or NSAIDs. However, patients in the csDMARD group reported more pain, fatigue, and headache compared to the other groups.
Anahtar Kelimeler
Coronavirus, rheumatic disease, autoimmune., Coronavirüs, COVID-19, romatizmal hastalık, otoimmün
Proje Numarası
yoktur
Kaynakça
- 1. Alzahrani ZA, Alghamdi KA. Clinical characteristics and outcome of COVID-19 in patients with rheumatic diseases. 2021;41(6):1097-103.
- 2. Atzeni F, Bendtzen K, Bobbio-Pallavicini F, Conti F, Cutolo M, Montecucco C, et al. Infections and treatment of patients with rheumatic diseases. Clinical and experimental rheumatology. 2008;26(1 Suppl 48):S67-73.
- 3. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet (London, England). 2020;395(10229):1033-4.
- 4. Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. 2020;369:m1849.
- 5. Pascarella G, Strumia A. COVID-19 diagnosis and management: a comprehensive review. 2020;288(2):192-206.
- 6. He F, Deng Y, Li W. Coronavirus disease 2019: What we know? Journal of medical virology. 2020;92(7):719-25.
- 7. Baj J, Karakuła-Juchnowicz H, Teresiński G, Buszewicz G, Ciesielka M, Sitarz E, et al. COVID-19: Specific and Non-Specific Clinical Manifestations and Symptoms: The Current State of Knowledge. J Clin Med. 2020;9(6):1753.
- 8. Leiva Sisnieguez CE, Espeche WG, Salazar MR. Arterial hypertension and the risk of severity and mortality of COVID-19. The European respiratory journal. 2020;55(6).
- 9. Chen M, Wei Y, Zhang Q, Wan Q, Chen X. Epidemiology and clinical characteristics of COVID-19 in rheumatic diseases at a tertiary care hospital in Wuhan, China. Clinical and experimental rheumatology. 2021;39(2):442-3.
- 10. Haberman RH, Castillo R, Chen A, Yan D, Ramirez D, Sekar V, et al. COVID-19 in Patients With Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Disease-Modifying Antirheumatic Drugs on Clinical Outcomes. Arthritis Rheumatol. 2020;72(12):1981-9.
